Keating Financial Advisory Services’s UroGen Pharma URGN Stock Holding History

Keating Financial Advisory Services’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74	Buy	+2	New	+$54	﹤0.01%	2493

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Keating Financial Advisory Services's URGN Position: Q2 2026 in Review

Keating Financial Advisory Services opened a new position in UroGen Pharma (URGN) in Q2 2026: 2 shares worth $74. The stake represents ﹤0.01% of the portfolio and ranks #2493 among its holdings.

189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Keating Financial Advisory Services held 2 shares of UroGen Pharma worth $74 as of Q2 2026.
UroGen Pharma was a new Keating Financial Advisory Services position in Q2 2026.
UroGen Pharma made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2493 holding.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.